Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate

Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, and Orano Med (formerly AREVA Med) a subsidiary of Orano, a nuclear biotech company developing innovative therapies in oncology, today announced that the two companies have entered into an agreement to combine certain proprietary technologies from each company to create a novel oncologic therapy.

As quoted in the press release:

The collaboration will focus on the development of novel phospholipid drug conjugates (PDC™) utilizing Orano Med’s unique alpha emitter, lead-212 (²¹²Pb), conjugated to Cellectar’s phospholipid ether (PLE). The companies intend to evaluate the new PDC in up to three oncology indications.

“We believe that the combination of Cellectar’s targeted delivery with Orano Med’s powerful alpha emitter offers the potential to create a novel and highly potent cancer therapy,” said James Caruso, chief executive officer of Cellectar Biosciences. “This collaboration is an ideal strategic fit and provides an excellent opportunity to expand our radiotherapeutic portfolio beyond CLR 131, a highly potent beta emitter, and establish one of the most complete oncology-focused radiotherapeutic portfolios.”

Click here to read the full press release.